Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ferring Acthrel to be launched in mid-summer; orphan drug is company's first U.S. approval.

Executive Summary

FERRING ACTHREL DIAGNOSTIC TO BE LAUNCHED IN MID-SUMMER at an expected cost of $275 per treatment (one 100 mcg vial), the company said. Corticorelin ovine triflutate for injection was approved May 23 for "use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome." The orphan indication covers approximately 63,000 patients per year, Ferring said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel